Triamcinolone associated with few side effects

Article

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events.

Intravitreal triamcinolone acetonide (IVTA) for the treatment of steroid-responsive disorders of the posterior segment is associated with a low incidence of serious vision-threatening adverse events, according to a report published in the January issue of Retina.

Daniel Roth of the Robert Wood Johnson Medical School, New Jersey, USA and colleagues retrospectively reviewed the medical records of 784 patients (929 consecutive eyes) who had received one or more IVTA injections for a steroid-responsive posterior segment disorder.

The most common adverse event occurring within three months of the initial injection was steroid-related ocular hypertension, with intraocular pressure spikes of >21 mmHg in 21% of eyes and >25 mmHg in 11% of eyes. Ocular inflammation was observed in six eyes (0.6%) and three eyes (0.3%) had corneal epithelial defects thought to be related to pretreatment with povidone-iodine solution. No eyes had culture-positive infectious endophthalmitis.

When administered under sterile conditions, concluded the authors, IVTA is associated with a low incidence of serious adverse events.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.